Xbrane Biopharma AB

Financial Performance

* Revenue for the quarter amounted to SEK 17.3 million (93.2), of which SEK 17.2 million (46.6) is attributable to product sales of Ximluci® and SEK 0.2 million (46.6) to licensing income. * Operating loss was SEK -10.5 million (profit 27.7). * EBITDA amounted to SEK -7.8 million (32.6). * Loss for the period was SEK -13.1 million (profit 8.2). *…

| FINANSIELLT SAMMANDRAG FÖR KONCERNEN | 2025 | 2024 | | :--- | :--- | :--- | | Nettoomsättning, TSEK | 152 354 | 148 098 | | Forskning- och utvecklingskostnader, TSEK | –117 865 | –162 014 | | FoU-kostnader i % av rörelsekostnader | 69% | 68% | | Rörelseresultat, TSEK | –28 248 | –97 224 | | EBITDA, TSEK | –13 647 | –77 335 | | Periodens resultat, TSEK | 127 242 | –266 220…